These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 39048172)

  • 1. Gambogic Acid Improves Cisplatin Resistance of Bladder Cancer Cells through the Epithelial-Mesenchymal Transition Pathway Mediated by the miR-205-5p/ZEB1 Axis.
    Mei Y; Xu J; Li W; Chen S
    Ann Clin Lab Sci; 2024 May; 54(3):354-362. PubMed ID: 39048172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells.
    Wang M; Zhang R; Zhang S; Xu R; Yang Q
    Gene; 2019 Jun; 700():110-119. PubMed ID: 30917930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA ADPGK-AS1 promotes pancreatic cancer progression through activating ZEB1-mediated epithelial-mesenchymal transition.
    Song S; Yu W; Lin S; Zhang M; Wang T; Guo S; Wang H
    Cancer Biol Ther; 2018 Jul; 19(7):573-583. PubMed ID: 29667486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-106a-5p alleviated the resistance of cisplatin in lung cancer cells by targeting Jumonji domain containing 6.
    Ge X; Jiang Y; Hu X; Yu X
    Transpl Immunol; 2021 Dec; 69():101478. PubMed ID: 34607003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
    Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
    Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
    [No Abstract]   [Full Text] [Related]  

  • 6. Gambogic Acid Inhibits Melanoma through Regulation of miR-199a-3p/ZEB1 Signalling.
    Liang L; Zhang Z; Qin X; Gao Y; Zhao P; Liu J; Zeng W
    Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):692-703. PubMed ID: 29959879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer.
    Okamura S; Yoshino H; Kuroshima K; Tsuruda M; Osako Y; Sakaguchi T; Yonemori M; Yamada Y; Tatarano S; Nakagawa M; Enokida H
    BMC Cancer; 2021 Jan; 21(1):48. PubMed ID: 33430801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition.
    Shao Q; Zhang P; Ma Y; Lu Z; Meng J; Li H; Wang X; Chen D; Zhang M; Han Y; Liu H; Ma S
    Gene; 2018 Apr; 652():48-58. PubMed ID: 29427737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
    Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
    Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
    Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
    EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and Functions of Formyl Peptide Receptor 1 in Drug-Resistant Bladder Cancer.
    Jiang X; Lei T; Zhang M
    Technol Cancer Res Treat; 2018 Jan; 17():1533034618769413. PubMed ID: 29665744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forkhead Box R2 Knockdown Decreases Chemoresistance to Cisplatin via MYC Pathway in Bladder Cancer.
    Li Y; Zu X; Hu X; Wang L; He W
    Med Sci Monit; 2019 Nov; 25():8928-8939. PubMed ID: 31761897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudogene OCT4-pg5 upregulates OCT4B expression to promote bladder cancer progression by competing with miR-145-5p.
    Zhou W; Yang Y; Wang W; Yang C; Cao Z; Lin X; Zhang H; Xiao Y; Zhang X
    Cell Cycle; 2024 Mar; 23(6):645-661. PubMed ID: 38842275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of lncRNA ZNRD1-AS1 inhibits progression of bladder cancer by regulating miR-194 and ZEB1.
    Gao Z; Li S; Zhou X; Li H; He S
    Cancer Med; 2020 Oct; 9(20):7695-7705. PubMed ID: 32862492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells.
    Zhang P; Liu H; Xia F; Zhang QW; Zhang YY; Zhao Q; Chao ZH; Jiang ZW; Jiang CC
    Int J Mol Med; 2014 Jan; 33(1):151-9. PubMed ID: 24173500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
    Liu B; Wang R; Liu H
    Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p.
    Lu W; Zhang H; Niu Y; Wu Y; Sun W; Li H; Kong J; Ding K; Shen HM; Wu H; Xia D; Wu Y
    Mol Cancer; 2017 Jul; 16(1):118. PubMed ID: 28697764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTBP1-mediated biogenesis of circATIC promotes progression and cisplatin resistance of bladder cancer.
    Huang C; Yang Y; Wang X; Chen S; Liu Z; Li Z; Tang X; Zhang Q
    Int J Biol Sci; 2024; 20(9):3570-3589. PubMed ID: 38993556
    [No Abstract]   [Full Text] [Related]  

  • 19. PAX2 mediated upregulation of ESPL1 contributes to cisplatin resistance in bladder cancer through activating the JAK2/STAT3 pathway.
    Zhang W; Wang Y; Tang Q; Li Z; Sun J; Zhao Z; Jiao D
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Sep; 397(9):6889-6901. PubMed ID: 38573552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA KCNQ1OT1 contributes to the cisplatin resistance of tongue cancer through the KCNQ1OT1/miR-124-3p/TRIM14 axis.
    Qiao CY; Qiao TY; Jin H; Liu LL; Zheng MD; Wang ZL
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):200-212. PubMed ID: 31957833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.